ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2007
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The report covers the three and nine-month periods ended March 31, 2007. The company operates globally with manufacturing in Australia, Germany, France, and the U.S.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Nine Months Ended Mar 31, 2007 |
|---|---|---|
| Net Revenue | $182.99 million | $525.02 million |
| Net Income (Loss) | ($15.37 million) | $38.63 million |
| Diluted EPS | ($0.20) | $0.49 |
| Gross Margin | 30% (Reported) | 51% (Reported) |
| Cash and Equivalents | $240.11 million (Balance Sheet) | N/A |
| Operating Cash Flow | N/A | $64.00 million |
| Total Debt | $114.57 million (Current + Long-term) | N/A |
Note: Reported gross margins are significantly depressed by a one-time voluntary product recall charge of $59.7 million. Excluding this charge, gross margin was 62% for the quarter and 63% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 13% year-over-year for the quarter and 20% for the nine-month period, driven by increased unit sales of flow generators and masks.
- Profitability Impact: The company reported a net loss of $15.4 million for the quarter, a reversal from a $26.4 million profit in the prior year quarter. This was primarily due to the $59.7 million voluntary product recall expense.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 16% for the quarter, and R&D expenses rose 43%, reflecting increased personnel, infrastructure investment, and currency appreciation impacts.
- Balance Sheet: Inventories increased 44% to $156.9 million to support sales growth and new product launches. Accounts receivable increased 20% to $153.1 million.
Guidance, Outlook, and Risks
- Product Recall: On April 23, 2007, ResMed initiated a worldwide voluntary recall of approximately 300,000 S8 flow generators due to a remote potential for short circuits and thermal damage. The estimated cost is $59.7 million, recognized in the current quarter. Management notes that actual costs could differ based on regulatory feedback.
- Outlook: Management expects SG&A expenses to remain in the range of 31% to 34% of net revenue and R&D expenses between 6% and 7%.
- Liquidity: The company maintains strong liquidity with $260.1 million in cash and marketable securities. It has a $75 million undrawn revolving credit facility and is in compliance with all debt covenants.
- Risks: Key risks include the potential for the recall costs to exceed estimates, reputational damage affecting future sales, and exposure to foreign currency exchange rate fluctuations.
Investor Verification Checklist
- Recall Cost Accuracy: Verify if the $59.7 million accrual for the S8 recall remains accurate as the company finalizes plans with regulatory authorities.
- Inventory Levels: Assess the 44% increase in inventory to ensure it aligns with sales velocity and does not signal future obsolescence risks.
- Reputation Impact: Monitor subsequent quarters for any decline in unit sales or market share resulting from the product recall and associated publicity.
- Currency Hedging: Review the effectiveness of foreign currency hedging strategies given the company's significant international exposure and recent currency impacts on expenses.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the total debt to EBITDA ratio, given the recent earnings volatility.